Clinical assessment and management of spasticity: a review

被引:87
作者
Rekand, T. [1 ]
机构
[1] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway
来源
ACTA NEUROLOGICA SCANDINAVICA | 2010年 / 122卷
关键词
Baclofen; Botulinum toxin; disability; intrathecal Baclofen; spasticity score; TOXIN TYPE-A; MODIFIED ASHWORTH SCALE; SPINAL-CORD-INJURY; QUALITY-OF-LIFE; BOTULINUM-TOXIN; LONG-TERM; INTRATHECAL BACLOFEN; INTERRATER RELIABILITY; CEREBRAL-PALSY; FOLLOW-UP;
D O I
10.1111/j.1600-0404.2010.01378.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Spasticity is a sign of upper motor neurone lesion, which can be located in the cerebrum or the spinal cord, and be caused by stroke, multiple sclerosis, spinal cord injury, brain injury, cerebral paresis, or other neurological conditions. Management is dependent on clinical assessment. Positive and negative effects of spasticity should be considered. Ashworth score and the modified Ashworth score are the most used scales for assessment of spasticity. These and other spasticity scales are based on assessment of resistance during passive movement. The main goal of management is functional improvement. A novel 100-point score to assess disability, function related to spasticity (Rekand disability and spasticity score) is proposed. Management of spasticity should be multimodal and should always include physiotherapy or exercise. Oral medications such as baclofen and tizanidine have limited efficacy and considerable side effects, but are easiest to use. Botulinum toxin combined with physiotherapy and/or orthopaedic surgery is effective treatment of localized spasticity. Treatment with intrathecal baclofen via programmable implanted pump is effective in generalized spasticity, particularly in the lower extremities. Neurosurgical and orthopaedic procedures may be considered in intractable cases.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 46 条
[1]
ASHWORTH B, 1964, PRACTITIONER, V192, P540
[2]
Focal spasticity therapy with botulinum toxin: Effects on function, activities of daily living and pain in 100 adult patients [J].
Bergfeldt, U ;
Borg, K ;
Kullander, K ;
Julin, P .
JOURNAL OF REHABILITATION MEDICINE, 2006, 38 (03) :166-171
[3]
SHORT FORM 36 ASSESSED HEALTH-RELATED QUALITY OF LIFE AFTER FOCAL SPASTICITY THERAPY [J].
Bergfeldt, Ulla ;
Skoeld, Camilla ;
Julin, Per .
JOURNAL OF REHABILITATION MEDICINE, 2009, 41 (04) :279-281
[4]
A MULTI-CENTRE, DOUBLE-BLIND TRIAL OF TIZANIDINE, A NEW ANTISPASTIC AGENT, IN SPASTICITY ASSOCIATED WITH HEMIPLEGIA [J].
BES, A ;
EYSSETTE, M ;
PIERROTDESEILLIGNY, E ;
ROHMER, F ;
WARTER, JM .
CURRENT MEDICAL RESEARCH AND OPINION, 1988, 10 (10) :709-718
[5]
Spasticity-assessment: a review [J].
Biering-Sorensen, F. ;
Nielsen, J. B. ;
Klinge, K. .
SPINAL CORD, 2006, 44 (12) :708-722
[6]
INTERRATER RELIABILITY OF A MODIFIED ASHWORTH SCALE OF MUSCLE SPASTICITY [J].
BOHANNON, RW ;
SMITH, MB .
PHYSICAL THERAPY, 1987, 67 (02) :206-207
[7]
Spasticity [J].
Brashear, Allison ;
Lambeth, Kelly .
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2009, 11 (03) :153-161
[8]
Effect of simultaneous Botulinum toxin injections into several muscles on impairment, activity, participation, and quality of life among stroke patients presenting with a stiff knee gait [J].
Caty, Gilles D. ;
Detrembleur, Christine ;
Bleyenheuft, Corinne ;
Deltombe, Thierry ;
Lejeune, Thierry M. .
STROKE, 2008, 39 (10) :2803-2808
[9]
INTRATHECAL BACLOFEN FOR INTRACTABLE SPASTICITY OF SPINAL ORIGIN - RESULTS OF A LONG-TERM MULTICENTER STUDY [J].
COFFEY, RJ ;
CAHILL, D ;
STEERS, W ;
PARK, TS ;
ORDIA, J ;
MEYTHALER, J ;
HERMAN, R ;
SHETTER, AG ;
LEVY, R ;
GILL, B ;
SMITH, R ;
WILBERGER, J ;
LOESER, JD ;
CHABAL, C ;
FELER, C ;
ROBERTSON, JT ;
PENN, RD ;
CLARKE, A ;
BURCHIEL, KJ ;
LEIBROCK, LG .
JOURNAL OF NEUROSURGERY, 1993, 78 (02) :226-232
[10]
Botulinum Toxin Type A With Oral Baclofen Versus Oral Tizanidine: A Nonrandomized Pilot Comparison in Patients With Cerebral Palsy and Spastic Equinus Foot Deformity [J].
Dai, Alper I. ;
Wasay, Mohammad ;
Awan, Safia .
JOURNAL OF CHILD NEUROLOGY, 2008, 23 (12) :1464-1466